Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Blood Disease

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44394   clinical trials with a EudraCT protocol, of which   7406   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    10,515 result(s) found for: Blood Disease. Displaying page 112 of 526.
    «« First « Previous 108  109  110  111  112  113  114  115  116  Next» Last»»
    EudraCT Number: 2018-000863-98 Sponsor Protocol Number: GlucoTab@MobileCare Start Date*: 2018-06-25
    Sponsor Name:Medical University of Graz
    Full Title: A single-centre, open-label, non-controlled trial of acceptance, usability, safety and efficacy of a tablet based workflow and decision support system with incorporated basal-insulin algorithm for ...
    Medical condition: Diabetes mellitus type 2
    Disease: Version SOC Term Classification Code Term Level
    20.0 10027433 - Metabolism and nutrition disorders 10067585 Type 2 diabetes mellitus PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2022-000933-18 Sponsor Protocol Number: HLSC-UCD-02 Start Date*: Information not available in EudraCT
    Sponsor Name:Unicyte AG
    Full Title: An Open-label, Non-controlled, Multi-center, Phase 2 Study to Assess the Efficacy and Safety of Allogeneic Human Liver Stem Cells (HLSCs) in the Treatment of Pediatric Patients with Early-onset Ure...
    Medical condition: Urea cycle disorders
    Disease: Version SOC Term Classification Code Term Level
    21.1 200000003094 10013373 Disorders of urea cycle metabolism LLT
    Population Age: Newborns, Infants and toddlers, Children, Under 18 Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2019-001961-34 Sponsor Protocol Number: ANRS173 Start Date*: 2019-07-10
    Sponsor Name:INSERM ANRS
    Full Title: ANRS 173 ALTAR A randomized, open-label, phase III trial comparing a dual nucleoside analogues strategy preceded by an induction period with an integrase inhibitor based triple therapy to an immedi...
    Medical condition: Hiv Infection
    Disease: Version SOC Term Classification Code Term Level
    20.1 10021881 - Infections and infestations 10020161 HIV infection PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: View results
    EudraCT Number: 2013-004333-33 Sponsor Protocol Number: 13HH1771 Start Date*: 2014-01-20
    Sponsor Name:Imperial College London
    Full Title: Phase 1 of dose escalation of extracorporeal shockwave treatment only and in combination DPP-4 inhibitor and parathyroid hormone (non-randomised, open-labelled) & Phase II of combination treatments...
    Medical condition: ischaemic cardiomyopathy
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004849 10077980 Chronic systolic heart failure LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: View results
    EudraCT Number: 2010-022445-20 Sponsor Protocol Number: CA204006 Start Date*: 2011-11-08
    Sponsor Name:Bristol-Myers Squibb International Corporation
    Full Title: A Phase 3, Randomized, Open Label Trial of Lenalidomide/dexamethasone With or Without Elotuzumab in Subjects with Previously Untreated Multiple Myeloma.
    Medical condition: Untreated Multiple Myeloma
    Disease: Version SOC Term Classification Code Term Level
    19.1 100000004864 10028228 Multiple myeloma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) HU (Completed) IE (Completed) GB (GB - no longer in EU/EEA) DE (Completed) ES (Completed) BE (Completed) AT (Completed) GR (Completed) IT (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2019-001336-62 Sponsor Protocol Number: 2019-ASPIREAF Start Date*: 2020-04-01
    Sponsor Name:Hamilton Health Sciences Corporation
    Full Title: Anticoagulation for Stroke Prevention In patients with Recent Episodes of perioperative Atrial Fibrillation after noncardiac surgery - The ASPIRE-AF trial
    Medical condition: Perioperative atrial fibrillation after noncardiac surgery
    Disease: Version SOC Term Classification Code Term Level
    22.1 100000004852 10042244 Stroke LLT
    20.0 100000004866 10005103 Bleeding LLT
    20.0 100000004849 10003663 Atrial flutter/ fibrillation LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Trial now transitioned) ES (Ongoing) IT (Trial now transitioned) NL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2018-000853-29 Sponsor Protocol Number: TRACE Start Date*: 2020-01-14
    Sponsor Name:Klinikum der Universität München
    Full Title: Treatment of chemo-refractory viral infections after allogeneic stem cell transplantation with multispecific T cells against CMV, EBV and AdV: A phase III, prospective, multicentre clinical trial
    Medical condition: Chemo-refactory AdV, CMV and EBV infections after allogeneic stem cell transplantation
    Disease: Version SOC Term Classification Code Term Level
    22.0 10042613 - Surgical and medical procedures 10067859 Allogenic stem cell transplantation PT
    20.1 10021881 - Infections and infestations 10011831 Cytomegalovirus infection PT
    21.1 10021881 - Infections and infestations 10060931 Adenovirus infection PT
    21.1 10021881 - Infections and infestations 10015108 Epstein-Barr virus infection PT
    Population Age: Infants and toddlers, Children, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Trial now transitioned) FR (Trial now transitioned) BE (Trial now transitioned) IT (Trial now transitioned) ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2015-000620-28 Sponsor Protocol Number: LPS14245 Start Date*: 2015-07-06
    Sponsor Name:sanofi-aventis groupe
    Full Title: A Multi-Country, Multicenter, Single-Arm, Open-Label Study to Document the Safety, Tolerability and Effect of Alirocumab on atherogenic lipoproteins in High Cardio-Vascular Risk Patients With Sever...
    Medical condition: Hypercholesterolemia
    Disease: Version SOC Term Classification Code Term Level
    19.0 10027433 - Metabolism and nutrition disorders 10020603 Hypercholesterolaemia PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed) CZ (Completed) SK (Completed) BE (Completed) IT (Completed) HU (Completed) AT (Completed) DE (Completed) FR (Completed) SE (Completed) ES (Completed) FI (Completed) PL (Completed) GR (Completed) SI (Completed)
    Trial results: View results
    EudraCT Number: 2020-003320-16 Sponsor Protocol Number: CEL-03 Start Date*: 2020-12-23
    Sponsor Name:CeleCor Therapeutics, Inc.
    Full Title: A Phase 3 prospective, blinded, randomized, placebo controlled, international multicenter study to assess the safety and efficacy of a single subcutaneous injection of zalunfiban in subjects with S...
    Medical condition: Subjects with documented STEMI, presenting with persistent ischemic chest pain (>10 minutes) and new ≥2 mm ST-segment elevation in 2 adjacent ECG leads, in whom the total duration of symptoms to di...
    Disease: Version SOC Term Classification Code Term Level
    20.0 10007541 - Cardiac disorders 10028593 Myocardial disorders HLGT
    20.0 10007541 - Cardiac disorders 10000891 Acute myocardial infarction PT
    20.0 10007541 - Cardiac disorders 10028600 Myocardial ischaemia PT
    21.0 10007541 - Cardiac disorders 10081099 Acute cardiac event PT
    23.1 100000004848 10062084 Platelet aggregation LLT
    20.1 10005329 - Blood and lymphatic system disorders 10050661 Platelet aggregation inhibition PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Trial now transitioned) CZ (Trial now transitioned) HU (Trial now transitioned) FR (Trial now transitioned) RO (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2015-005471-24 Sponsor Protocol Number: GINECO-OV236b Start Date*: 2016-04-19
    Sponsor Name:ARCAGY-GINECO
    Full Title: A randomized, double-blinded, phase III study of atezolizumab versus placebo in patients with late relapse of epithelial ovarian, fallopian tube, or peritoneal cancer treated by platinum-based chem...
    Medical condition: Patients with late relapse of epithelial ovarien cancer, fallopian tube or peritoneal cancer treated with chemotherapy , bevacizumab and a anti PD-L1
    Disease: Version SOC Term Classification Code Term Level
    19.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10016180 Fallopian tube cancer PT
    19.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10066697 Ovarian cancer recurrent PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: FR (Completed) ES (Ongoing) AT (Completed) DE (Completed) BE (Completed) CZ (Completed)
    Trial results: View results
    EudraCT Number: 2018-002342-36 Sponsor Protocol Number: JHL-CLIN-1101-03 Start Date*: 2019-02-01
    Sponsor Name:JHL Biotech (Hong Kong) Limited
    Full Title: A Multinational, Randomized, Double-blind, Positive-controlled, Parallel Group Clinical Study to Compare the Efficacy and Safety of the JHL1101 in Combination with CHOP (J-CHOP) versus Rituximab in...
    Medical condition: Diffuse Large B-Cell Lymphoma (DLBCL)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10012818 Diffuse large B-cell lymphoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) CZ (Prematurely Ended) HU (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2015-005317-68 Sponsor Protocol Number: ACE-CL-208 Start Date*: 2016-05-16
    Sponsor Name:Acerta Pharma B.V.
    Full Title: A Phase 2 Study of the Efficacy and Safety of ACP-196 in Subjects with Relapsed/Refractory CLL and Intolerant of Ibrutinib Therapy
    Medical condition: High Risk Chronic Lymphocytic Leukemia
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10008976 Chronic lymphocytic leukemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) BE (Completed) ES (Completed) FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2008-008555-41 Sponsor Protocol Number: INSULA Start Date*: 2011-05-26
    Sponsor Name:Universitätsklinikum Essen
    Full Title: Comparative study of the effect of intranasal insulin on memory deficits in type 2 diabetes and early Alzheimer´s dementia (INSULA)
    Medical condition: Early Alzheimer´s dementia (eAD), type 2 diabetes mellitus with amnestic mild cognitive impairment (T2D-aMCI), healthy controls (Co)
    Disease: Version SOC Term Classification Code Term Level
    17.1 10029205 - Nervous system disorders 10012271 Dementia Alzheimer's type PT
    17.1 100000004861 10045242 Type II diabetes mellitus LLT
    Population Age: Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2017-004233-86 Sponsor Protocol Number: V160-002 Start Date*: 2018-09-06
    Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
    Full Title: Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3- Dose Regimen of V160 (Cytomegaloviru...
    Medical condition: Cytomegalovirus infection (CMVi)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004862 10009703 CMV infection LLT
    Population Age: Adolescents, Under 18, Adults Gender: Female
    Trial protocol: FI (Completed) ES (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2018-003355-38 Sponsor Protocol Number: D0816C00025 Start Date*: 2019-12-05
    Sponsor Name:AstraZeneca AB
    Full Title: A Phase I, Open-label, Parallel Group Study to Investigate Olaparib Safety and Tolerability, Efficacy and Pharmacokinetics in Paediatric Patients with Solid Tumours
    Medical condition: Solid Tumours
    Disease:
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) DE (Completed) ES (Ongoing) DK (Trial now transitioned) HU (Trial now transitioned) IT (Trial now transitioned) AT (Prematurely Ended) PL (Completed)
    Trial results: View results
    EudraCT Number: 2004-004513-41 Sponsor Protocol Number: PKU-004 Start Date*: 2005-10-25
    Sponsor Name:BioMarin Pharmaceutical Inc.
    Full Title: A Phase 3, Multicenter, Open-Label Extension Study of Phenoptin in Subjects with Phenylketonuria Who Have Elevated Phenylalanine Levels
    Medical condition: Phenylketonuria (PKU)
    Disease: Version SOC Term Classification Code Term Level
    6.1 10034872
    Population Age: Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) IE (Completed) IT (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2016-002077-35 Sponsor Protocol Number: EC-HEM-HGUGM-2016-01 Start Date*: 2017-05-05
    Sponsor Name:José Luís Díez Martín
    Full Title: CLINICAL TRIAL PHASE I / II, SINGLE-CENTER, HISTORICAL CONTROL, TO EVALUATE THE EFFECTIVENESS OF DONOR IL-15-STIMULATED NK CELLS POST TRANSPLANT INFUSION, IN ACUTE LEUKEMIA PATIENTS WITH POOR PROGN...
    Medical condition: High risk acute myeloid leukemia
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2011-002507-15 Sponsor Protocol Number: GS-US-259-0116 Start Date*: 2012-06-22
    Sponsor Name:Gilead Sciences, Inc.
    Full Title: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of the Effects of Ranolazine on Major Adverse Cardiovascular Events in Subjects with a History of Chronic Angina Who Undergo Percutaneo...
    Medical condition: Coronary artery disease
    Disease: Version SOC Term Classification Code Term Level
    17.0 10007541 - Cardiac disorders 10011078 Coronary artery disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) SE (Completed) CZ (Completed) AT (Completed) GB (Completed) BE (Completed) NL (Completed) ES (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2020-001250-21 Sponsor Protocol Number: 2020/3078 Start Date*: 2020-04-03
    Sponsor Name:GUSTAVE ROUSSY
    Full Title: COVID-19 - Epidemiology of SARS-CoV-2 and Mortality to Covid19 Disease upon Hydroxychloroquine and Azithromycin Therapy in French Cancer patients
    Medical condition: Patients eligible for, or under, or recently treated by chemotherapy (CT) and/or immune-checkpoint blockade (ICB) for the treatment of solid tumors or hematological malignancies.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2004-001621-16 Sponsor Protocol Number: 04516 Start Date*: 2007-08-26
    Sponsor Name:University College London (UCL)
    Full Title: An intergroup randomised trial of rituximab versus a watch and wait strategy in patients with advanced stage, asymptomatic, non-bulky fillicular lymphoma
    Medical condition: Advanced stage, asymptomatic, non-bulky follicular lymphoma (grades 1, 2 and 3a)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 108  109  110  111  112  113  114  115  116  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Tue May 26 19:20:53 CEST 2026 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA